Nektar Therapeutics has a targeted portfolio of novel therapeutics that target cytokine pathways and other mechanisms to selectively modulate the immune system and to advance the treatment of cancer, autoimmune disorders, and chronic inflammatory conditions.
Nektar is also engaged in a series of co-development and commercialization collaborations with pharmaceutical industry leaders and emerging biotech companies.
1L Metastatic Melanoma
1L Metastatic Renal Cell Carcinoma
Muscle-Invasive Bladder Cancer Who Are Cisplatin Ineligible
1L Metastatic Head and Neck Squamous Cell Carcinoma
1L Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Cancer
1L Advanced Renal Cell Carcinoma
1L Metastatic Non-Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Relapsed/Refractory Metastatic Melanoma
Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Metastatic Colorectal Cancer or Metastatic Head and Neck Cancer
Systemic Lupus Erythematosus